Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

NCT06230523

Eli Lilly · Phase 2 · Completed · Enrollment 263

NCT06230523

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebon/rn/rn/rn/r
1 mg Eloralintiden/rn/rn/rn/r
3 mg Eloralintiden/rn/rn/rn/r
6 mg Eloralintiden/rn/rn/rn/r
9 mg Eloralintiden/rn/rn/rn/r
6/9 mg Eloralintiden/rn/rn/rn/r
3/6/9 mg Eloralintiden/rn/rn/rn/r

Not shown

  • Placebo: endpoint not reported
  • 1 mg Eloralintide: endpoint not reported
  • 3 mg Eloralintide: endpoint not reported
  • 6 mg Eloralintide: endpoint not reported
  • 9 mg Eloralintide: endpoint not reported
  • 6/9 mg Eloralintide: endpoint not reported
  • 3/6/9 mg Eloralintide: endpoint not reported